2nd Supplement to the Shareholders’ Agreement in relation to the Parties’ share portfolios in CureVac N.V. (NL-Amsterdam) dated 16 June 2020 as amended by the 1st Supplement dated 14 August 2020 between KfW Palmengartenstr. 5-9 60325 Frankfurt am Main...Shareholders’ Agreement • January 13th, 2022 • Dievini Hopp BioTech Holding GmbH & Co KG • Pharmaceutical preparations
A On 16 June 2020, the Parties (except for DH-LT) entered into a shareholders’ agreement in relation to the Parties’ share portfolios in CureVac N.V. (NL-Amsterdam). DH-LT acceded to such shareholders’ agreement under a supplement to the shareholders’ agreement dated 14 August 2020 (“1st Supplement”) (the shareholders’ agreement as amended by the 1st Supplement is referred to as the “Shareholders’ Agreement”).
Information identifying certain issuers has been excluded from this exhibit because it is both not material and is the type that the Reporting Persons treat as private or confidential. Accession Agreement between dievini Hopp BioTech holding GmbH &...Accession Agreement • February 22nd, 2022 • Dievini Hopp BioTech Holding GmbH & Co KG • Pharmaceutical preparations
JOINT FILING STATEMENTJoint Filing Agreement • February 11th, 2022 • Dievini Hopp BioTech Holding GmbH & Co KG • Biological products, (no disgnostic substances)
In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the undersigned hereby agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the common shares of Immatics N.V. and further agree that this Joint Filing Agreement be included as an exhibit to such joint filing.
JOINT FILING STATEMENTJoint Filing Agreement • February 12th, 2021 • Dievini Hopp BioTech Holding GmbH & Co KG • Biological products, (no disgnostic substances)
In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the undersigned hereby agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the common shares of Immatics N.V. and further agree that this Joint Filing Agreement be included as an exhibit to such joint filing.
ContractAccession Agreement • March 17th, 2022 • Dievini Hopp BioTech Holding GmbH & Co KG • Pharmaceutical preparations
Information identifying certain issuers has been excluded from this exhibit because it is both not material and is the type that the Reporting Persons treat as private or confidential.
JOINT FILING STATEMENTJoint Filing Agreement • February 14th, 2017 • Dievini Hopp BioTech Holding GmbH & Co KG • Pharmaceutical preparations
In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the undersigned hereby agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the common shares of AC Immune SA and further agree that this Joint Filing Agreement be included as an exhibit to such joint filing.
Accession Agreement to the Shareholders’ Agreement relating to CureVac N.V.Accession Agreement • May 5th, 2022 • Dievini Hopp BioTech Holding GmbH & Co KG • Pharmaceutical preparations
JOINT FILING STATEMENTJoint Filing Agreement • May 5th, 2022 • Dievini Hopp BioTech Holding GmbH & Co KG • Pharmaceutical preparations
In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the undersigned hereby agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the common shares of CureVac N.V. and further agree that this Joint Filing Agreement be included as an exhibit to such joint filing.
JOINT FILING STATEMENTJoint Filing Agreement • October 15th, 2021 • Dievini Hopp BioTech Holding GmbH & Co KG • Pharmaceutical preparations
In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the undersigned hereby agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the common shares of CureVac N.V. and further agree that this Joint Filing Agreement be included as an exhibit to such joint filing.
Pool Agreement on the pooling of shares in CureVac N.V. between dievini Hopp BioTech holding GmbH & Co. KG, Johann-Jakob-Astor-Str. 57, 69190 Walldorf, Germany - hereinafter referred to as “dievini” - and DH-LT-Investments GmbH, Opelstrasse 28, 68789...Pool Agreement • February 22nd, 2022 • Dievini Hopp BioTech Holding GmbH & Co KG • Pharmaceutical preparations
JOINT FILING STATEMENTJoint Filing Agreement • August 24th, 2020 • Dievini Hopp BioTech Holding GmbH & Co KG • Pharmaceutical preparations
In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the undersigned hereby agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the common shares of CureVac N.V. and further agree that this Joint Filing Agreement be included as an exhibit to such joint filing.
JOINT FILING STATEMENTJoint Filing Agreement • February 22nd, 2022 • Dievini Hopp BioTech Holding GmbH & Co KG • Pharmaceutical preparations
In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the undersigned hereby agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the common shares of CureVac N.V. and further agree that this Joint Filing Agreement be included as an exhibit to such joint filing.
JOINT FILING STATEMENTJoint Filing Agreement • March 17th, 2022 • Dievini Hopp BioTech Holding GmbH & Co KG • Pharmaceutical preparations
In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the undersigned hereby agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the common shares of CureVac N.V. and further agree that this Joint Filing Agreement be included as an exhibit to such joint filing.
